Summary:
Sensorion will lead a symposium on advancements in hearing loss treatments at the 36th World Congress of Audiology in Paris.
Key Takeaways:
- The symposium will focus on hearing preservation and gene therapy for congenital hearing disorders.
- Leading experts will discuss the latest therapeutic advances in ototoxicity and cochlear implantation.
- The event will explore the future impact of these new therapies on patient care.
Sensorion, a clinical-stage biotechnology company that specializes in the development of novel therapies to restore, treat, and prevent within the field of hearing loss disorders, will participate in the 36th World Congress of Audiology (WCA), taking place in Paris, France, September 19-22, 2024.
On this occasion, Sensorion will host a symposium on September 20, 2024, at 12.30pm CET, entitled, “Are we at the Dawn of a Hearing Loss Revolution?”
Further Reading: Sensorion Gets Positive Recommendation for Clinical Trial of Drug Candidate for Cisplatin-Induced Ototoxicity
The event will be hosted by Professor Natalie Loundon, ENT surgeon in the pediatric Hospital Necker-Enfants malades in Paris, France. The symposium will be comprised of three sessions:
Sensorion Symposium 1st Session:
Hearing Preservation: Relevant Medical Progress in Cisplatin-Induced Ototoxicity and the Loss of the Residual Hearing following Cochlear Implantation
This session will focus on the therapeutic advances in hearing preservation associated with cisplatin-induced ototoxicity and following cochlear implantation. Professor Yann Nguyen, ENT surgeon, Hôpital de la Pitié Salpêtrière, Paris, France; and Professor Stephen O’Leary, head of Otolaryngology at the University of Melbourne, Melbourne, Australia, will co-present this session.
Sensorion Symposium 2nd Session:
Gene therapy: A Ray of Hope for Congenital Hearing Disorders
This session will address gene therapy applied to patients suffering from congenital profound deafness and will be presented by Professor Catherine Birman, otorhinolaryngologist, director of the Sydney Cochlear Implant Centre, Sydney, Australia.
Sensorion Symposium 3rd Session:
Conclusion: What Does the Future Hold for these New Therapies?
This session will be led by Professor Natalie Loundon, pediatric otorhinolaryngologist, director of the Cochlear Implant and Audiology Unit, Necker-Enfants malades, Paris, France, and will address the impact these new therapies will have on patient management, followed by a question-and-answer session.
About Sensorion
Sensorion is a clinical-stage biotech company that specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion, according to the company, has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear-related diseases, enabling it to select the best targets and mechanisms of action for drug candidates.
